Search

The benzonaphthyridine derivative, AH 21-132, has non-specific relaxant effects in isolated airways smooth muscle. The action of AH 21-132 in trachealis muscle is not antagonised by propranolol but AH 21-132 is slightly potentiated by epithelium removal. Electrophysiological recording from guinea-pig trachealis shows that AH 21-132-induced relaxation is accompanied by suppression of electrical slow waves and by cellular hyperpolarisation. Unlike theophylline, AH 21-132 does not cause spasm of cooled (12 degrees C), indomethacin-treated trachealis muscle, nor does it act as an antagonist at adenosine A1 receptors. AH 21-132 does not depress the Ca2+ sensitivity or responsiveness of Triton X-100 skinned trachealis fibres. In tracheal relaxant concentrations, AH 21-132 selectively inhibits cAMP phosphodiesterase (PDE) compared with cGMP-PDE. The (-)-enantiomer of AH 21-132 is more potent than its (+)-enantiomer both in causing tracheal relaxation and in inhibiting cAMP-PDE. When tested on PDE isoenzymes separated from bovine trachealis and guinea-pig cardiac ventricles, AH 21-132 exhibits selectivity as an inhibitor of the isoenzyme types III and IV. AH 21-132 increases the trachealis content of cAMP and cGMP, but only in concentration greater than that required fully to suppress the mechanical tone of the tissue. AH 21-132 has bronchodilator activity in anaesthetised, ventilated guinea-pigs when administered intraduodenally, intravenously or by inhalation. Inhaled AH 21-132 also provides bronchodilatation in healthy human volunteers in whom bronchoconstriction has been induced by inhaled methacholine.

The properties and physiological roles of K+-channels in the plasmalemma of airways smooth muscle are currently being clarified by the use of techniques such as patch-clamp recording. K+-channel activity plays an important role in determining both the resting membrane potential and the electrical excitability of the airways smooth muscle cell. Established bronchodilators such as agonists at beta-adrenoceptors and methylxanthines may provide K+-channel opening but this is not crucial for their relaxant action. The actions of other smooth muscle relaxants such as BRL 34915 and pinacidil (Fig.) may more closely depend on their ability to open K+-channels and such agents are currently being examined to determine whether they protect against bronchoconstrictor challenge in vivo or have beneficial effects in asthma.